8.13
+0.12
(1.50%)
Jun 19 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 7.86 - 8.25 |
| 52 week | 5.42 - 11.36 |
| Open | 8.03 |
| Vol / Avg. | 0.00/959,160.00 |
| Mkt cap | 647.58M |
| P/E | - |
| Div/yield | - |
| EPS | -0.64 |
| Shares | 79.65M |
| Beta | 0.75 |
| Inst. own | 126% |
Events
Aug 5, 2013
Q2 2013 Achillion Pharmaceuticals Inc. Earnings Release
Jun 18, 2013
Achillion Pharmaceuticals Inc. at Wells Fargo Health Care Conference
May 30, 2013
Achillion Pharmaceuticals Inc. at Deutsche Bank dbAccess Health Care Conference
May 30, 2013
Achillion Pharmaceuticals Inc. Achillion Nominates ACH-3422 as Nucleotide for the Treatment of Chronic HCV - Conference Call
May 28, 2013
Achillion Pharmaceuticals Inc. Annual Shareholder Meeting
May 21, 2013
Achillion Pharmaceuticals Inc. at UBS Global Healthcare Conference
May 15, 2013
Achillion Pharmaceuticals Inc. at Bank of America Merrill Lynch Health Care Conference
May 6, 2013
Q1 2013 Achillion Pharmaceuticals Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | -1807.71% |
| Operating margin | - | -1814.08% |
| EBITD margin | - | -1798.43% |
| Return on average assets | -32.77% | -57.42% |
| Return on average equity | -35.26% | -65.90% |
| Employees | 56 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.
Officers and directors
| David I. Scheer | Chairman of the Board | |
| Milind S. Deshpande Ph.D. | President, Chief Executive Officer, Director | |
| Mary Kay Kay Fenton CPA, MBA | Chief Financial Officer, Senior Vice President | |
| Gautam Shah Ph.D. | Executive Vice President, Chief Compliance Officer | |
| David Apelian M.D., Ph.D. | Executive Vice President, Chief Medical Officer | |
| Joseph Truitt MBA | Senior Vice President, Chief Commercial Officer | |
| Michael D. Kishbauch MBA | Director | |
| Jason S. Fisherman M.D. | Independent Director | |
| Gary E Frashier | Independent Director | |
| Kurt C Graves | Independent Director |